COMPANY |
Revance Therapeutics, Inc. |
COURT |
United States District Court for the Northern District of California |
CASE NUMBER |
21-cv-09585 |
JUDGE |
The Honorable Araceli Martinez-Olguin |
CLASS PERIOD |
November 25, 2019 - October 11, 2021 |
SECURITY TYPE |
Securities |
Case Background:
A class action lawsuit has been filed on behalf of those who purchased or acquired Revance Therapeutics, Inc. (“Revance”) (NASDAQ: RVNC) securities between November 25, 2019 and October 11, 2021, both dates inclusive (the “Class Period”).
The complaint alleges that throughout the Class Period, the Defendants made false and/or misleading statements and/or failed to disclose that: (1) quality control deficiencies existed at Revance’s manufacturing facility for DAXI; (2) the foregoing deficiencies decreased the likelihood that the FDA would approve the DAXI BLA in its current form; (3) accordingly, it was unlikely that the DAXI BLA would obtain FDA approval within the timeframe Revance had represented to investors; and (4) as a result, Revance’s public statements were materially false and misleading at all relevant times.
Current Status of Case:
On January 23, 2023, the Defendants filed a Motion to Dismiss the Action. The Motion has been fully briefed and the Court held oral argument on August 10, 2023. The Motion is still pending before the Court. This action is ongoing.
If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.